Many drugs that target amyloid-β (Aβ) in Alzheimer disease (AD) have failed to demonstrate
clinical efficacy. However, four anti-Aβ antibodies have been shown to mediate the removal …

Alzheimer's disease (AD) is the most prevalent form of age-related dementia in the world,
and its main pathological features consist of amyloid-β (Aβ) plaque deposits and …

Background Monoclonal antibodies that target amyloid-beta (Aβ) have the potential to slow
cognitive and functional decline in persons with early Alzheimer's disease. Gantenerumab is …

Immunotherapy against amyloid-beta (Aβ) is a promising option for the treatment of
Alzheimer's disease (AD). Aβ exists as various species, including monomers, oligomers …

Protein misfolding and aggregation is observed in many amyloidogenic diseases affecting
either the central nervous system or a variety of peripheral tissues. Structural and dynamic …

Alzheimer's disease (AD) is the most common neurodegenerative disease in the elderly
worldwide. However, the complexity of AD pathogenesis leads to discrepancies in the …

Alzheimer disease (AD) accounts for 60–70% of dementia cases. Given the seriousness of
the disease and continual increase in patient numbers, developing effective therapies to …

The body of evidence suggesting a causative, initiating role of beta amyloid (Aβ) in the
pathogenesis of Alzheimer's disease (AD) is substantial. Yet, only a few anti-amyloid agents …

After years of failed attempts to develop a disease-modifying therapy for Alzheimer's
disease, consistent evidence in support of clinical efficacy was finally presented for a …

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by memory loss
and personality changes, eventually leading to dementia. The pathological hallmarks of AD …